Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

The use of focused cardiac ultrasound to screen for occult heart disease in asymptomatic cats.

Loughran KA, Rush JE, Rozanski EA, Oyama MA, Larouche-Lebel É, Kraus MS.

J Vet Intern Med. 2019 Sep;33(5):1892-1901. doi: 10.1111/jvim.15549. Epub 2019 Jul 17.

2.

Plasma and tissue angiotensin-converting enzyme 2 activity and plasma equilibrium concentrations of angiotensin peptides in dogs with heart disease.

Larouche-Lebel É, Loughran KA, Oyama MA, Solter PF, Laughlin DS, Sánchez MD, Assenmacher CA, Fox PR, Fries RC.

J Vet Intern Med. 2019 Jul;33(4):1571-1584. doi: 10.1111/jvim.15548. Epub 2019 Jun 28.

3.

Echocardiographic indices and severity of mitral regurgitation in dogs with preclinical degenerative mitral valve disease.

Larouche-Lebel É, Loughran KA, Oyama MA.

J Vet Intern Med. 2019 Mar;33(2):489-498. doi: 10.1111/jvim.15461. Epub 2019 Feb 22.

4.

A systematic review of specialist inpatient dementia care services versus standard inpatient dementia care in acute hospitals.

McCausland BMS, Patel HP, Amin J, Baldwin DS, Loughran K, Osman-Hicks VC.

Aging Clin Exp Res. 2019 May;31(5):595-610. doi: 10.1007/s40520-018-1021-y. Epub 2018 Sep 26.

5.

Living with incurable cancer: what are the rehabilitation needs in a palliative setting?

Loughran K, Rice S, Robinson L.

Disabil Rehabil. 2019 Apr;41(7):770-778. doi: 10.1080/09638288.2017.1408709. Epub 2017 Nov 29.

PMID:
29185362
6.

Circulating exosome microRNA associated with heart failure secondary to myxomatous mitral valve disease in a naturally occurring canine model.

Yang VK, Loughran KA, Meola DM, Juhr CM, Thane KE, Davis AM, Hoffman AM.

J Extracell Vesicles. 2017 Jul 12;6(1):1350088. doi: 10.1080/20013078.2017.1350088. eCollection 2017.

7.

Association between high expression macrophage migration inhibitory factor (MIF) alleles and West Nile virus encephalitis.

Das R, Loughran K, Murchison C, Qian F, Leng L, Song Y, Montgomery RR, Loeb M, Bucala R.

Cytokine. 2016 Feb;78:51-4. doi: 10.1016/j.cyto.2015.11.021. Epub 2015 Nov 28.

8.

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL.

PLoS One. 2012;7(8):e41936. doi: 10.1371/journal.pone.0041936. Epub 2012 Aug 3.

9.

Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.

Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, Jarbadan NR, Baab KT, Liao J, Wang HG, Kester M, Desai D, Amin S, Loughran TP Jr, Liu X.

Blood. 2011 Sep 8;118(10):2793-800. doi: 10.1182/blood-2011-01-331447. Epub 2011 Jul 18.

10.

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.

Jaoko W, Karita E, Kayitenkore K, Omosa-Manyonyi G, Allen S, Than S, Adams EM, Graham BS, Koup RA, Bailer RT, Smith C, Dally L, Farah B, Anzala O, Muvunyi CM, Bizimana J, Tarragona-Fiol T, Bergin PJ, Hayes P, Ho M, Loughran K, Komaroff W, Stevens G, Thomson H, Boaz MJ, Cox JH, Schmidt C, Gilmour J, Nabel GJ, Fast P, Bwayo J.

PLoS One. 2010 Sep 21;5(9):e12873. doi: 10.1371/journal.pone.0012873.

11.

Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia.

Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, Jarbadan NR, Broeg K, Zhang R, Liao J, Sayers TJ, Kester M, Loughran TP Jr.

Blood. 2010 Nov 18;116(20):4192-201. doi: 10.1182/blood-2010-02-271080. Epub 2010 Jul 29.

12.

A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modified vaccinia Ankara virus vaccine candidate in Indian volunteers.

Ramanathan VD, Kumar M, Mahalingam J, Sathyamoorthy P, Narayanan PR, Solomon S, Panicali D, Chakrabarty S, Cox J, Sayeed E, Ackland J, Verlinde C, Vooijs D, Loughran K, Barin B, Lombardo A, Gilmour J, Stevens G, Smith MS, Tarragona-Fiol T, Hayes P, Kochhar S, Excler JL, Fast P.

AIDS Res Hum Retroviruses. 2009 Nov;25(11):1107-16. doi: 10.1089/aid.2009.0096.

PMID:
19943789
13.

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, Mahmoud A, Pinheiro S, Gillespie G, Brown D, Loach V, Roberts J, Guimaraes-Walker A, Hayes P, Loughran K, Smith C, De Bont J, Verlinde C, Vooijs D, Schmidt C, Boaz M, Gilmour J, Fast P, Dorrell L, Hanke T, McMichael AJ.

J Virol. 2006 May;80(10):4717-28.

14.

Trial-related discrimination in HIV vaccine clinical trials.

Allen M, Israel H, Rybczyk K, Pugliese MA, Loughran K, Wagner L, Erb S.

AIDS Res Hum Retroviruses. 2001 May 20;17(8):667-74.

PMID:
11429107
15.

Novel mechanism of inhibition of elastase by beta-lactams is defined by two inhibitor crystal complexes.

Taylor P, Anderson V, Dowden J, Flitsch SL, Turner NJ, Loughran K, Walkinshaw MD.

J Biol Chem. 1999 Aug 27;274(35):24901-5.

16.

Effects of polyethylene glycol 400 (PEG 400) following 13 weeks of gavage treatment in Fischer-344 rats.

Hermansky SJ, Neptun DA, Loughran KA, Leung HW.

Food Chem Toxicol. 1995 Feb;33(2):139-49.

PMID:
7868000

Supplemental Content

Loading ...
Support Center